Individuals with sickle cell disease have severe anemia due to the production of abnormal hemoglobin S, chronic red blood cell hemolysis, and increased oxidative stress leading to endothelial cell dysfunction, vasculopathy, and progressive organ damage. The transcription factor NRF2 (erythroid-derived 2)-like 2) is a master regulator of antioxidant proteins; under low oxidative stress, NRF2 is sequestered in the cytoplasm by Kelch-like ECH-associated protein 1, β-transducin repeat-containing protein or HRD1, and directed to the proteasome for degradation. When cells are exposed to oxidative stress, NRF2 is released from these repressor proteins, translocates to the nucleus, and activates antioxidant genes to suppress cellular reactive oxidant species and inflammation. In erythroid progenitors, NRF2 also modulates fetal hemoglobin expression through direct binding in the γ-globin promoter and modification of chromatin structure in the β-globin locus. In sickle erythroid cells, NRF2 provides unique benefits through fetal hemoglobin induction to inhibit hemoglobin S polymerization and protection against oxidative stress due to chronic hemolysis. Thus, development of small chemical molecules that activate NRF2 has the potential to ameliorate the clinical severity of sickle cell disease. In this review, we discuss progress towards understanding NRF2 regulation and strategies to develop agents for the treatment of sickle cell disease.
Impact statement
Sickle cell disease (SCD) is a group of inherited blood disorders caused by mutations in the human β-globin gene, leading to the synthesis of abnormal hemoglobin S, chronic hemolysis, and oxidative stress. Inhibition of hemoglobin S polymerization by fetal hemoglobin holds the greatest promise for treating SCD. The transcription factor NRF2, is the master regulator of the cellular oxidative stress response and activator of fetal hemoglobin expression. In animal models, various small chemical molecules activate NRF2 and ameliorate the pathophysiology of SCD. This review discusses the mechanisms of NRF2 regulation and therapeutic strategies of NRF2 activation to design the treatment options for individuals with SCD.
RotherRPBellLHillmenPGladwinMT.The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA2005;
293:1653–62
SiesHBerndtCJonesDP.Oxidative stress. Annu Rev Biochem2017;
86:715–48
5.
NathKAGrandeJPHaggardJJCroattAJKatusicZSSoloveyAHebbelRP.Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol2001;
158:893–903
6.
RyterSWAlamJChoiAM.Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev2006;
86:583–650
7.
SiegelDGustafsonDLDehnDLHanJYBoonchoongPBerlinerLJRossD.NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol2004;
65:1238–47
8.
VoskouSAslanMFanisPPhylactidesMKleanthousM.Oxidative stress in β-thalassaemia and sickle cell disease. Redox Biol2015;
6:226–39
9.
GhoshSTanFYuTLiYAdisaOMosunjacMOfori-AcquahSF.Global gene expression profiling of endothelium exposed to heme reveals an organ-specific induction of cytoprotective enzymes in sickle cell disease. PLoS One2011;
6:e18399
10.
NguyenTNioiPPickettCB.The NRF2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem2009;
284:13291–5
11.
ChorleyBNCampbellMRWangXKaracaMSambandanDBanguraFXuePPiJKleebergerSRBellDA.Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucl Acids Res2012;
40:7416–29
12.
RushmoreTHMortonMRPickettCB.The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem1991;
266:11632–9
13.
SunJBrandMZenkeYTashiroSGroudineMIgarashiK.Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc Natl Acad Sci U S A2004;
101:1461–6
14.
DhakshinamoorthySJainAKBloomDAJaiswalAK.Bach1 competes with NRF2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J Biol Chem2005;
280:16891–900
15.
RayPDHuangBWTsujiY.Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal2012;
24:981–90
16.
MaQ.Role of NRF2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol2013;
53:401–26
17.
ReddyNMKleebergerSRYamamotoMKenslerTWScollickCBiswalSReddySP.Genetic dissection of the NRF2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection. Physiol Genom2007;
32:74–81
18.
KenslerTWWakabayashiNBiswalS.Cell survival responses to environmental stresses via the KEAP1-NRF2-ARE pathway. Annu Rev Pharmacol Toxicol2007;
47:89–116
19.
ChenZHSaitoYYoshidaYSekineANoguchiNNikiE.4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of NRF2. J Biol Chem2005;
280:41921–7
20.
IshiiTItohKTakahashiSSatoHYanagawaTKatohYBannaiSYamamotoM.Transcription factor NRF2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem2000;
275:16023–9
21.
MitsuishiYTaguchiKKawataniYShibataTNukiwaTAburataniHYamamotoMMotohashiH.NRF2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell2012;
22:66–79
22.
LeeJMChanKKanYWJohnsonJA.Targeted disruption of NRF2 causes regenerative immune-mediated hemolytic anemia. Proc Natl Acad Sci U S A2004;
101:9751–6
23.
ItohKWakabayashiNKatohYIshiiTIgarashiKEngelJDYamamotoM.KEAP1 represses nuclear activation of antioxidant responsive elements by NRF2 through binding to the amino-terminal Neh2 domain. Genes Dev1999;
13:76–86
24.
MillsELRyanDGPragHADikovskayaDMenonDZaslonaZJedrychowskiMPCostaASHHigginsMHamsESzpytJRuntschMCKingMSMcGouranJFFischerRKesslerBMMcGettrickAFHughesMMCarrollRGBootyLMKnatkoEVMeakinPJAshfordMLJModisLKBrunoriGSévinDCFallonPGCaldwellSTKunjiERSChouchaniETFrezzaCDinkova-KostovaATHartleyRCMurphyMPO'NeillLA.Itaconate is an anti-inflammatory metabolite that activates NRF2 via alkylation of KEAP1. Nature2018;
556:113–7
25.
OoiADykemaKAnsariAPetilloDSniderJKahnoskiRAnemaJCraigDCarptenJTehBTFurgeKA.CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res2013;
73:2044–51
26.
AdamJHatipogluEO'FlahertyLTernetteNSahgalNLockstoneHBabanDNyeEStampGWWolhuterKStevensMFischerRCarmelietPMaxwellPHPughCWFrizzellNSogaTKesslerBMEl-BahrawyMRatcliffePJPollardPJ.Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and NRF2 signaling. Cancer Cell2011;
20:524–37
27.
KomatsuMKurokawaHWaguriSTaguchiKKobayashiAIchimuraYSouYSUenoISakamotoATongKIKimMNishitoYIemuraSNatsumeTUenoTKominamiEMotohashiHTanakaKYamamotoM.The selective autophagy substrate p62 activates the stress responsive transcription factor NRF2 through inactivation of KEAP1. Nat Cell Biol2010;
12:213–23
28.
LauAWangXJZhaoFVilleneuveNFWuTJiangTSunZWhiteEZhangDD.A noncanonical mechanism of NRF2 activation by autophagy deficiency: direct interaction between KEAP1 and p62. Mol Cell Biol2010;
30:3275–85
29.
JiangTHarderBRojo de la VegaMWongPKChapmanEZhangDD.p62 links autophagy and NRF2 signaling. Free Radic Biol Med2015;
88:199–204
MeakinPJChowdhrySSharmaRSAshfordFBWalshSVMcCrimmonRJDinkova-KostovaATDillonJFHayesJDAshfordML.Susceptibility of NRF2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol2014;
34:3305–20
32.
McMahonMThomasNItohKYamamotoMHayesJD.Redox-regulated turnover of NRF2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem2004;
279:31556–67
33.
ChowdhrySZhangYMcMahonMSutherlandCCuadradoAHayesJD.NRF2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene2013;
32:3765–81
34.
RadaPRojoAIChowdhrySMcMahonMHayesJDCuadradoA.SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the NRF2 transcription factor in a KEAP1-independent manner. Mol Cell Biol2011;
31:1121–33
35.
SalazarMRojoAIVelascoDde SagarraRMCuadradoA.Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor NRF2. J Biol Chem2006;
281:14841–51
36.
GameiroIMichalskaPTentiGCoresÁBuendiaIRojoAIGeorgakopoulosNDHernández-GuijoJMTeresa RamosMWellsGLópezMGCuadradoAMenéndezJCLeónR.Discovery of the first dual GSK3β inhibitor/NRF2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. Sci Rep2017;
7:45701
37.
Keleku-LukweteNSuzukiMYamamotoM.An overview of the advantages of KEAP1-NRF2 system activation during inflammatory disease treatment. Antioxid Redox Signal2018;
29:1746–55
38.
ZhangXSHaSWangXLShiYLDuanSSLiZA.Tanshinone IIA protects dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity through miR-153/NF-E2-related factor 2/antioxidant response element signaling pathway. Neuroscience2015;
303:489–502
39.
XueWLBaiXZhangL.rhTNFR:Fc increases NRF2 expression via miR-27a mediation to protect myocardium against sepsis injury. Biochem Biophys Res Commun2015;
464:855–61
40.
WangNZhangLLuYZhangMZhangZWangKLvJ.Down-regulation of microRNA-142-5p attenuates oxygen-glucose deprivation and reoxygenation-induced neuron injury through up-regulating NRF2/ARE signaling pathway. Biomed Pharmacother2017;
89:1187–95
41.
YangMYaoYEadesGZhangYZhouQ.MiR-28 regulates NRF2 expression through a KEAP1-independent mechanism. Breast Cancer Res Treat2011;
129:983–91
42.
HuangXGaoYQinJLuS.The role of miR-34a in the hepatoprotective effect of hydrogen sulfide on ischemia/reperfusion injury in young and old rats. PLoS One2014;
9:e113305
43.
ZhouSYeWZhangYYuDShaoQLiangJZhangM.miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting NRF2-dependent antioxidant pathway. Am J Transl Res2016;
8:2992–3002
44.
ZhouCZhaoLZhengJWangKDengHLiuPChenLMuH.MicroRNA-144 modulates oxidative stress tolerance in SH-SY5Y cells by regulating nuclear factor erythroid 2-related factor 2-glutathione axis. Neurosci Lett2017;
655:21–7
45.
YuMLiuYZhangBShiYCuiLZhaoX.Inhibiting microRNA-144 abates oxidative stress and reduces apoptosis in hearts of streptozotocin-induced diabetic mice. Cardiovasc Pathol2015;
24:375–81
46.
SangokoyaCTelenMJChiJT.microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood2010;
116:4338–48
DeNicolaGM1KarrethFAHumptonTJGopinathanAWeiCFreseKMangalDYuKHYeoCJCalhounESScrimieriFWinterJMHrubanRHIacobuzio-DonahueCKernSEBlairIATuvesonDA.Oncogene-induced NRF2 transcription promotes ROS detoxification and tumorigenesis. Nature2011;
475:106–9
50.
KansanenEKuosmanenSMLeinonenHLevonenAL.The KEAP1-NRF2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol2013;
1:45–9
51.
TaoSWangSMoghaddamSJOoiAChapmanEWongPKZhangDD.Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res2014;
74:7430–41
52.
MiaoWHuLScrivensPJBatistG.Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem2005;
280:20340–8
ZhuXXiCThomasBPaceBS.Loss of NRF2 function exacerbates the pathophysiology of sickle cell disease in a transgenic mouse model. Blood2018;
131:558–62
57.
Keleku-LukweteNSuzukiMOtsukiATsuchidaKKatayamaSHayashiMNaganumaEMoriguchiTTanabeOEngelJDImaizumiMYamamotoM.Amelioration of inflammation and tissue damage in sickle cell model mice by NRF2 activation. Proc Natl Acad Sci U S A2015;
112:12169–74
58.
KrishnamoorthySPaceBGuptaDSturtevantSLiBMakalaLBrittainJMooreNVieiraBThullenTStoneILiHHobbsWELightDR.Dimethyl fumarate increases fetal hemoglobin, provides vascular protection and heme detoxification and corrects anemia in sickle cell disease. JCI Insight2017;
2:pii:96409
59.
MacariERLowreyCH.Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood2011;
117:5987–97
60.
ZhuXLiBPaceBS.NRF2 mediates γ-globin gene regulation and fetal hemoglobin induction in human erythroid progenitors. Haematologica2017;
102:e285–8
61.
KhanAFornesOStiglianiAGheorgheMCastro-MondragonJAvan der LeeRBessyAChènebyJKulkarniSRTanGBaranasicDArenillasDJSandelinAVandepoeleKLenhardBBallesterBWassermanWWParcyFMathelierA.JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res2018;
46:D1284
62.
MacariERSchaefferEKWestRJLowreyCH.Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cell. Blood2013;
121:830–9
63.
LessardSBeaudoinMBenkiraneKLettreG.Comparison of DNA methylation profiles in human fetal and adult red blood cell progenitors. Genome Med2015;
7:1
64.
LanaroCFranco-PenteadoCFAlbuquequeDMSaadSTConranNCostaFF.Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol2009;
85:235–42
65.
DossJFJonassaintJCGarrettMEAshley-KochAETelenMJChiJT.Phase 1 study of a sulforaphane-containing broccoli sprout homogenate for sickle cell disease. PLoS One2016;
11:e0152895
66.
ChavanHOrugantiMKrishnamurthyP.The ATP-binding cassette transporter ABCB6 is induced by arsenic and protects against arsenic cytotoxicity. Toxicol Sci2011;
120:519–28
67.
FerreiraGCFrancoRLloydSGMouraIMouraJJHuynhBH.Structure and function of ferrochelatase. J Bioenerg Biomembr1995;
27:221–9
68.
CordovaEJValenzuelaOLSánchez-PeñaLCEscamilla-GuerreroGHernández-ZavalaAOrozcoLDel RazoLM.Nuclear factor erythroid 2-related factor gene variants and susceptibility of arsenic-related skin lesions. Hum Exp Toxicol2014;
33:582–9
69.
MacLeodAKMcmahonMPlummerSMHigginsLGPenningTMIgarashiKHayesJD.Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis2009;
30:1571–80
70.
WuKCCuiJYKlaassenCD.Beneficial role of NRF2 in regulating NADPH generation and consumption. Toxicol Sci2011;
123:590–600
71.
RajagopalARaoAUAmigoJTianMUpadhyaySKHallCUhmSMathewMKFlemingMDPawBHKrauseMHamzaI.Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins. Nature2008;
453:1127–31
72.
WinterbournCC.The biological chemistry of hydrogen peroxide. Meth Enzymol2013;
528:3–25
73.
CampbellMRKaracaMAdamskiKNChorleyBNWangXBellDA.Novel hematopoietic target genes in the NRF2-mediated transcriptional pathway. Oxid Med Cell Longev2013;
2013:120305
74.
KatoGJSteinbergMHGladwinMT.Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest2017;
127:750–60
75.
SunXOuZChenRNiuXChenDKangRTangD.Activation of the p62-KEAP1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology2016;
63:173–84
76.
FormanHJZhangHRinnaA.Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med2009;
30:1–12
77.
YePMimuraJOkadaTSatoHLiuTMaruyamaAOhyamaCItohK.NRF2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol2014;
34:3421–34
78.
KaelinWGJrMcKnightSL.Influence of metabolism on epigenetics and disease. Cell2013;
153:56–69
79.
XiaoMYangHXuWMaSLinHZhuHLiuLLiuYYangCXuYZhaoSYeDXiongYGuanKL.Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev2012;
26:1326–38
80.
NiiharaYZerezCRAkiyamaDSTanakaKR.Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol1998;
58:117–21
81.
NiiharaYMillerSTKanterJLanzkronSSmithWRHsuLLGordeukVRViswanathanKSarnaikSOsunkwoIGuillaumeESadanandanSSiegerLLaskyJLPanosyanEHBlakeOANewTNBellevueRTranLTRazonRLStarkCWNeumayrLDVichinskyEP.Investigators of the phase 3 trial of l-glutamine in sickle cell disease. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med2018;
379:226–35
82.
RomeroRSayinVIDavidsonSMBauerMRSinghSXLeBoeufSEKarakousiTREllisDCBhutkarASánchez-RiveraFJSubbarajLMartinezBBronsonRTPriggeJRSchmidtEEThomasCJGoparajuCDaviesADolgalevIHeguyAAllajVPoirierJTMoreiraALRudinCMPassHIVander HeidenMGJacksTPapagiannakopoulosT.KEAP1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med2017;
23:1362–8
83.
SayinVILeBoeufSESinghSXDavidsonSMBiancurDGuzelhanBSAlvarezSWWuWLKarakousiTRZavitsanouAMUbriacoJMuirAKaragiannisDMorrisPJThomasCJPossematoRVander HeidenMGPapagiannakopoulosT.Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. Elife2017;
6:pii:e28083
84.
YuDdos SantosCOZhaoGJiangJAmigoJDKhandrosEDoreLCYaoYD'SouzaJZhangZGhaffariSChoiJFriendSTongWOrangeJSPawBHWeissMJ.miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev2010;
24:1620–33
85.
KimMTanYSChengWCKingsburyTJHeimfeldSCivinCI.MIR144 and MIR451 regulate human erythropoiesis via RAB14. Br J Haematol2015;
168:583–97
86.
YangHMagilnickNLeeCKalmazDOuXChanJYLuSC.Nrf1 and NRF2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1. Mol Cell Biol2005;
25:5933–46
87.
LiBTorresCMTakezakiMNeunertCKutlarAPaceBS.Micro rna profiling to identify regulator of fetal hemoglobin expression in sickle cell disease. Blood2014;
124:49
AbedDAGoldsteinMAlbanyanHJinHHuL.Discovery of direct inhibitors of KEAP1-NRF2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B2015;
5:285–99
90.
BelcherJDChenCNguyenJZhangPAbdullaFNguyenPKilleenTXuPO'SullivanGNathKAVercellottiGM.Control of oxidative stress and inflammation in sickle cell disease with the NRF2 activator dimethyl fumarate. Antioxid Redox Signal2017;
26:748–62
91.
HoppeCKuypersFLarkinSHagarWVichinskyEStylesL.A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol2011;
153:655–63
92.
KuppermanELeeECCaoYBannermanBFitzgeraldMBergerAYuJYangYHalesPBruzzeseFLiuJBlankJGarciaKTsuCDickLFlemingPYuLManfrediMRolfeMBolenJ.Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res2010;
70:1970–80
93.
PullarkatVMengZTaharaSMJohnsonCSKalraVK.Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the NRF2 pathway. Hemoglobin2014;
38:188–95
94.
DoddSDeanOCopolovDLMalhiGSBerkM. N-
acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther2008;
8:1955–62
95.
ManandharSChoJMKimJAKenslerTWKwakMK.Induction of NRF2-regulated genes by 3H-1, 2-dithiole-3-thione through the ERK signaling pathway in murine keratinocytes. Eur J Pharmacol2007;
577:17–27
96.
ZhangYTalalayPChoCGPosnerGH.A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A1992;
89:2399–403
97.
MrowietzUChristophersEAltmeyerP.Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol1998;
138:456–60
98.
StangelMLinkerRA.Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Expert Rev Clin Pharmacol2013;
6:355–62
TurleyAE1ZagorskiJW2RockwellCE3.The NRF2 activator tBHQ inhibits T cell activation of primary human CD4 T cells. Cytokine2015;
71:289–95
101.
DuaneWCHunninghakeDBFreemanMLPoolerPASchlasnerLAGebhardRL.Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology1988;
8:1147–50
102.
LiNAlamJVenkatesanMIEiguren-FernandezASchmitzDDi StefanoESlaughterNKilleenEWangXHuangAWangMMiguelAHChoASioutasCNelAE.NRF2 is a key transcription factor that regulates antioxidant defense in macrophages and epithelial cells: protecting against the proinflammatory and oxidizing effects of diesel exhaust chemicals. J Immunol2004;
173:3467–81
103.
NurEBrandjesDPTeerlinkTOttenHMOude ElferinkRPMuskietFEversLMten CateHBiemondBJDuitsAJSchnogJJ.Curama Study Group N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann Hematol2012;
91:1097–105
104.
JoepWRSFijnvandraatKRijneveldAWBoomMBKerkhoffsJ-Lvan MeursAHDe GrootMRHeijboerHDresseM-FFersterAHermansPVanderfaeillieAVan Den NesteEWSamantha BenghiatFHowardJKesse-AduRDelannoyAEfiraAAzeradM-Ade BorgieCAJMBiemondBJ.N-acetylcysteine in patients with sickle cell disease: a randomized controlled trial. Blood2016;
128:123
105.
CharacheSTerrinMLMooreRDDoverGJBartonFBEckertSVMcMahonRPBondsDR.Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med1995;
332:1317–22
106.
AtagaKIKutlarAKanterJLilesDCancadoRFriedrischJGuthrieTHKnight-MaddenJAlvarezOAGordeukVRGualandroSColellaMPSmithWRRollinsSAStockerJWRotherRP.Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med2017;
376:429–39
107.
KutlarAKanterJLilesDKAlvarezOACançadoRDFriedrischJRKnight-MaddenJMBruederleAShiMZhuZAtagaKI.Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol2019;
94:55–61
108.
AtwehGFSuttonMNassifIBoosalisVDoverGJWallensteinSWrightEMcMahonLStamatoyannopoulosGFallerDVPerrineSP.Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood1999;
93:1790–7
109.
SaunthararajahYHilleryCALavelleDMolokieRDornLBresslerLGavazovaSChenYHHoffmanRDeSimoneJ.Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood2003;
102:3865–70
110.
KutlarAReidMEInatiATaherATAbboudMREl-BeshlawyABuchananGRSmithHAtagaKIPerrineSPGhalieRG.A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol2013;
88:E255–60
111.
ReidMEEl BeshlawyAInatiAKutlarAAbboudMRHaynesJJrWardRSharonBTaherATSmithWManwaniDGhalieRG.A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol2014;
89:709–13
112.
MolokieRLavelleDGowhariMPaciniMKrauzLHassanJIbanezVRuizMANgKPWoostPRadivoyevitchTPacelliDFadaSRumpMHsiehMTisdaleJFJacobbergerJPhelpsMEngelJDSarafSHsuLLGordeukVDeSimoneJ.Saunthararajah Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med2017;
14:e1002382
113.
WangYYYangYXZheHHeZXZhouSF.Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther2014;
8:2075–88
114.
WardCMLiBPaceBS.Stable expression of miR-34a mediates fetal hemoglobin induction in K562 cells. Exp Biol Med2016;
241:719–29
